Pulmatrix Inc (PULM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulmatrix Inc (PULM) has a cash flow conversion efficiency ratio of -0.297x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($3.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PULM stock market capitalisation for the company's overall valuation and market capitalisation.
Pulmatrix Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Pulmatrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pulmatrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmatrix Inc ranked by their cash flow conversion efficiency. Explore Pulmatrix Inc (PULM) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hansa Investment Company Ltd
LSE:HANA
|
0.324x |
|
Combigene AB
ST:COMBI
|
-0.087x |
|
VIA OPTRONICS AG SP.ADS/1
F:5UU1
|
N/A |
|
Ace Digital AS
OL:ACED
|
N/A |
|
Exact Therapeutics AS
OL:EXTX
|
-0.697x |
|
Qualitech Public Company Limited
BK:QLT
|
-0.038x |
|
Wickes Group PLC
LSE:WIX
|
1.293x |
|
FBS Global Limited Ordinary Shares
NASDAQ:FBGL
|
N/A |
Annual Cash Flow Conversion Efficiency for Pulmatrix Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Pulmatrix Inc from 2012 to 2025. View Pulmatrix Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.81 Million | $-5.43 Million | -1.426x | -19.06% |
| 2024-12-31 | $8.95 Million | $-10.72 Million | -1.198x | -34.83% |
| 2023-12-31 | $18.00 Million | $-15.98 Million | -0.888x | -42.77% |
| 2022-12-31 | $31.11 Million | $-19.36 Million | -0.622x | -49.66% |
| 2021-12-31 | $47.45 Million | $-19.73 Million | -0.416x | +22.93% |
| 2020-12-31 | $23.14 Million | $-12.48 Million | -0.539x | -284.04% |
| 2019-12-31 | $11.02 Million | $3.23 Million | 0.293x | +120.71% |
| 2018-12-31 | $11.84 Million | $-16.76 Million | -1.415x | +0.91% |
| 2017-12-31 | $10.14 Million | $-14.48 Million | -1.428x | +5.52% |
| 2016-12-31 | $8.76 Million | $-13.24 Million | -1.512x | -295.18% |
| 2015-12-31 | $32.61 Million | $-12.47 Million | -0.383x | -88.47% |
| 2014-12-31 | $14.63 Million | $-2.97 Million | -0.203x | 0.00% |
| 2013-12-31 | $14.63 Million | $-2.97 Million | -0.203x | +97.76% |
| 2012-12-31 | $47.00K | $-426.00K | -9.064x | -- |
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.… Read more